Insights on the Antisense and RNA Interference Therapeutics Market Report & Forecast to 2028 - by Players, Types, Applications and Region
QYResearch released a latest market research report on the Global and United States Antisense and RNA Interference Therapeutics market, which is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the Global Antisense and RNA Interference Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
Scope of the Antisense and RNA Interference Therapeutics Market Report
This report focuses on global and United States Antisense and RNA Interference Therapeutics market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Antisense and RNA Interference Therapeutics market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, RNA accounting for % of the Antisense and RNA Interference Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, General Hospitals was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
For more information about this report, visit
Key Questions Answered in This Report
How has the Global and United States Antisense and RNA Interference Therapeutics performed so far and how will it perform in the coming years?
What are the key regional markets?
What is the breakup of the market based on the Antisense and RNA Interference Therapeutics type?
What is the breakup of the market based on the application?
What is the breakup of the market size based on the region?
What is the breakup of the market based on the region Level & country Level?
Who are the key players of the Global and United States Antisense and RNA Interference Therapeutics?
Segments Covered in the Report
Segment by Type
RNA
Antisense RNA
Segment by Application
General Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Alnylam Pharmaceuticals
Antisense Therapeutics
Arbutus Biopharma
Ionis Pharmaceuticals
F. Hoffmann-La Roche
Santaris
Silence Therapeutics
Sirnaomics
Tekmira Pharmaceuticals
Key Topics Covered
1 Study Coverage
2 Antisense and RNA Interference Therapeutics by Platform
3 Antisense and RNA Interference Therapeutics by Application
4 Global Antisense and RNA Interference Therapeutics Competitor Landscape by Company
5 Global Antisense and RNA Interference Therapeutics Market Size by Region
5.1 Global Antisense and RNA Interference Therapeutics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Antisense and RNA Interference Therapeutics Market Size by Region (2017-2028)
5.2.1 Global Antisense and RNA Interference Therapeutics Market Size by Region: 2017-2022
5.2.2 Global Antisense and RNA Interference Therapeutics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Antisense and RNA Interference Therapeutics Market Size YoY Growth 2017-2028
6.1.2 North America Antisense and RNA Interference Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Antisense and RNA Interference Therapeutics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Antisense and RNA Interference Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Antisense and RNA Interference Therapeutics Market Size YoY Growth 2017-2028
6.3.2 Europe Antisense and RNA Interference Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Antisense and RNA Interference Therapeutics Market Size YoY Growth 2017-2028
6.4.2 Latin America Antisense and RNA Interference Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Antisense and RNA Interference Therapeutics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Antisense and RNA Interference Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Corporation Information
7.1.2 Alnylam Pharmaceuticals Description and Business Overview
7.1.3 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Products Offered
7.1.5 Alnylam Pharmaceuticals Recent Development
7.2 Antisense Therapeutics
7.2.1 Antisense Therapeutics Corporation Information
7.2.2 Antisense Therapeutics Description and Business Overview
7.2.3 Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Antisense Therapeutics Antisense and RNA Interference Therapeutics Products Offered
7.2.5 Antisense Therapeutics Recent Development
7.3 Arbutus Biopharma
7.3.1 Arbutus Biopharma Corporation Information
7.3.2 Arbutus Biopharma Description and Business Overview
7.3.3 Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Arbutus Biopharma Antisense and RNA Interference Therapeutics Products Offered
7.3.5 Arbutus Biopharma Recent Development
7.4 Ionis Pharmaceuticals
7.4.1 Ionis Pharmaceuticals Corporation Information
7.4.2 Ionis Pharmaceuticals Description and Business Overview
7.4.3 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Products Offered
7.4.5 Ionis Pharmaceuticals Recent Development
7.5 F. Hoffmann-La Roche
7.5.1 F. Hoffmann-La Roche Corporation Information
7.5.2 F. Hoffmann-La Roche Description and Business Overview
7.5.3 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.5.4 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Products Offered
7.5.5 F. Hoffmann-La Roche Recent Development
7.6 Santaris
7.6.1 Santaris Corporation Information
7.6.2 Santaris Description and Business Overview
7.6.3 Santaris Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Santaris Antisense and RNA Interference Therapeutics Products Offered
7.6.5 Santaris Recent Development
7.7 Silence Therapeutics
7.7.1 Silence Therapeutics Corporation Information
7.7.2 Silence Therapeutics Description and Business Overview
7.7.3 Silence Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Silence Therapeutics Antisense and RNA Interference Therapeutics Products Offered
7.7.5 Silence Therapeutics Recent Development
7.8 Sirnaomics
7.8.1 Sirnaomics Corporation Information
7.8.2 Sirnaomics Description and Business Overview
7.8.3 Sirnaomics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Sirnaomics Antisense and RNA Interference Therapeutics Products Offered
7.8.5 Sirnaomics Recent Development
7.9 Tekmira Pharmaceuticals
7.9.1 Tekmira Pharmaceuticals Corporation Information
7.9.2 Tekmira Pharmaceuticals Description and Business Overview
7.9.3 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Products Offered
7.9.5 Tekmira Pharmaceuticals Recent Development
For more information about this report, visit
Any questions or requirements, please do not hesitate to contact us.
About Us:
QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 15 years’ experience and professional research team in various cities over the world，QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 59,000 clients across five continents. Let’s work closely with you and build a bold and better future.
Contact Us
QY Research
E-mail: global@qyresearch.com
Tel: +1-626-842-1666(US) +852-5808-0956 (HK)
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
Website: https://us.qyresearch.com